Literature DB >> 7467400

Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil after oral administration in mice.

M Iigo, A Nakamura, K Kuretani, A Hoshi.   

Abstract

1. The metabolic fate of a new antitumour agent, 1-hexylcarbamoyl-5-fluoro[6-14C]uracil (14C-HCFU) was compared with that of 5-fluoro[6-14C]uracil (14C-FU) after oral administration to mice. 2. 1-(5-Hydroxyhexylcarbamoyl)-5-fluorouracil (5-hydroxy-HCFU) and 1-(5-oxohexylcarbamoyl)-5-fluorouracil (5-keto-HCFU) were found as major intermediate metabolites of 14C-HCFU and were produced by omega-1 oxidation. 3. FU was detected in plasma 180 min after oral administration of 14C-HCFU, whereas unchanged FU disappeared within 60 min after 14C-FU. 4. 14C-HCFU and resulting FU were retained in tissues for a long period after oral administration, while administered 14C-FU was rapidly degraded.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7467400     DOI: 10.3109/00498258009033815

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.

Authors:  M Iigo; A Hoshi; H Kitagawa
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity.

Authors:  Natalia Realini; Carlos Solorzano; Chiara Pagliuca; Daniela Pizzirani; Andrea Armirotti; Rosaria Luciani; Maria Paola Costi; Tiziano Bandiera; Daniele Piomelli
Journal:  Sci Rep       Date:  2013-01-08       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.